2-(4-methoxybenzylamino)-6-methyl-4-(phenylamino)pyrido[4,3-d]pyrimidin-5(6H)-one | 1300609-28-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: 2-(4-methoxybenzylamino)-6-methyl-4-(phenylamino)pyrido[4,3-d]pyrimidin-5(6H)-one
• 英文别名: 4-Anilino-2-[(4-methoxyphenyl)methylamino]-6-methylpyrido[4,3-d]pyrimidin-5-one
• CAS: 1300609-28-2
• 化学式: C₂₂H₂₁N₅O₂
• 分子量: 387.441
• InChiKey: OUVXBTJBINCTLH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  79.4
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• KINASE INHIBITORS
  申请人：Kim Hong Woo

  公开号：US20110269739A1

  公开（公告）日：2011-11-03

  The present invention provides a new group of protein kinase inhibitors, pyrido[4,3,-d]pyrimidin-5-one derivatives, and pharmaceutically acceptable salts thereof that are useful for intreating cell proliferative disease and disorder such as cancer, autoimmune diseases, infection, cardiovascular disease and neurodegenerative disease and disorder. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor. The invention also provides useful intermediates generated during the syntheses of the pyrido[4,3,-d]pyrimidin-5-one derivatives.

  本发明提供了一种新的蛋白激酶抑制剂，即吡啶并[4,3,-d]嘧啶-5-酮衍生物及其药学上可接受的盐，可用于治疗细胞增殖性疾病和紊乱，如癌症、自身免疫疾病、感染、心血管疾病和神经退行性疾病和紊乱。本发明提供了合成和给药蛋白激酶抑制剂化合物的方法。本发明还提供了包含至少一种蛋白激酶抑制剂化合物和其药学上可接受的载体、稀释剂或赋形剂的药物制剂。本发明还提供在吡啶并[4,3,-d]嘧啶-5-酮衍生物合成过程中产生的有用中间体。
• US8404677B2
  申请人：——

  公开号：US8404677B2

  公开（公告）日：2013-03-26
• [EN] KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES
  申请人：GENOSCO

  公开号：WO2011053861A1

  公开（公告）日：2011-05-05

  The present invention provides a new group of protein kinase inhibitors, pyrido[4,3,-d]pyrimidin-5-one derivatives, and pharmaceutically acceptable salts thereof that are useful for intreating cell proliferative disease and disorder such as cancer, autoimmune diseases, infection, cardiovascular disease and neurodegenerative disease and disorder. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor. The invention also provides useful intermediates generated during the syntheses of the pyrido[4,3,-d]pyrimidin-5-one derivatives.